Kangmei Pharmaceutical Balance Sheet

Financials in millions CNY. Fiscal year is January - December.

Millions CNY. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Cash & Equivalents	1,240	977.84	1,057	1,507	2,419
Trading Asset Securities	0.09	0.08	0.08	0.12	0.52
Cash & Short-Term Investments	1,240	977.92	1,057	1,508	2,419
Cash Growth	26.82%	-7.45%	-29.90%	-37.68%	337.98%
Accounts Receivable	2,424	2,542	2,249	2,046	1,460
Other Receivables	451.27	823.86	874.44	888.79	1,052
Receivables	2,876	3,366	3,123	2,935	2,512
Inventory	2,237	2,510	2,644	2,751	3,195
Prepaid Expenses	-	-	-	0	-
Other Current Assets	299.05	45.65	-14.11	190.85	158.8
Total Current Assets	6,651	6,900	6,810	7,384	8,285
Property, Plant & Equipment	3,451	3,500	3,875	4,180	4,642
Long-Term Investments	1.04	1.11	1.15	1.39	1
Goodwill	36.91	106.35	106.35	106.35	106.35
Other Intangible Assets	413.93	409.47	491.02	529.79	579.73
Long-Term Deferred Tax Assets	64.17	74.36	101.48	96.97	60.69
Long-Term Deferred Charges	49.99	55.05	66.47	86.71	110.22
Other Long-Term Assets	2,551	2,752	2,829	2,783	2,269
Total Assets	13,220	13,798	14,280	15,169	16,054
Accounts Payable	2,355	2,546	2,256	2,563	2,015
Accrued Expenses	70.85	520.42	716.97	1,328	1,134
Short-Term Debt	90.93	15.83	26.14	25.62	15.17
Current Portion of Long-Term Debt	23.54	-	-	-	-
Current Portion of Leases	-	28.35	40.71	39.12	36.89
Current Income Taxes Payable	425.57	27.7	24.74	26.2	140.5
Current Unearned Revenue	91.7	118.82	159.89	158.12	193.85
Other Current Liabilities	2,208	2,637	2,875	1,301	1,411
Total Current Liabilities	5,266	5,894	6,100	5,442	4,947
Long-Term Leases	69.89	94.95	188.16	199.13	153.22
Long-Term Unearned Revenue	523.01	555.78	618.68	653.98	692.97
Long-Term Deferred Tax Liabilities	19.3	26.85	51.68	55.53	-
Other Long-Term Liabilities	16.25	17.79	241.31	1,835	293.02
Total Liabilities	5,894	6,589	7,200	8,185	6,086
Common Stock	13,829	13,864	13,864	13,864	13,864
Additional Paid-In Capital	18,474	18,783	18,783	18,783	18,783
Retained Earnings	-24,356	-24,367	-24,375	-24,478	-21,790
Treasury Stock	-659.92	-1,107	-1,225	-1,222	-932.82
Comprehensive Income & Other	3.23	1.18	1.18	1.43	3.1
Total Common Equity	7,290	7,174	7,048	6,948	9,927
Minority Interest	35.4	34.55	32.89	35.43	41.92
Shareholders' Equity	7,325	7,209	7,080	6,984	9,968
Total Liabilities & Equity	13,220	13,798	14,280	15,169	16,054
Total Debt	184.36	139.13	255.01	263.87	205.29
Net Cash (Debt)	1,056	838.8	801.68	1,244	2,214
Net Cash Growth	25.87%	4.63%	-35.54%	-43.82%	-
Net Cash Per Share	0.07	0.06	0.08	0.09	0.16
Filing Date Shares Outstanding	19,770	13,864	13,864	13,864	13,864
Total Common Shares Outstanding	19,770	13,864	13,864	13,864	13,864
Working Capital	1,386	1,007	709.67	1,942	3,338
Book Value Per Share	0.37	0.52	0.51	0.50	0.72
Tangible Book Value	6,839	6,658	6,450	6,312	9,240
Tangible Book Value Per Share	0.35	0.48	0.47	0.46	0.67
Buildings	-	5,119	5,229	5,401	5,665
Machinery	-	1,162	1,162	826.65	1,206
Construction In Progress	-	175.32	210.56	215.5	263.65

Source: S&P Global Market Intelligence. Standard template. Financial Sources.